Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 04 2025
0mins
Source: PRnewswire
FDA Approval for IBI3032: Innovent Biologics has received FDA approval to initiate Phase 1 clinical trials for IBI3032, a novel oral GLP-1 receptor agonist aimed at treating insulin-related metabolic diseases. The trials are set to begin in the second half of 2025 in both China and the U.S.
Innovent's Commitment to Innovation: The development of IBI3032 reflects Innovent's strong R&D capabilities and commitment to providing effective treatment options globally, with the potential to address various conditions beyond diabetes and obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
